Crizotinib

Today is World Lung Cancer Day.

Discussion about lung cancer research breakthroughs dominated the social media conversation among health care professionals during this year’s ASCO Annual Meeting.

In this video, Ghayas C. Issa, MD, assistant professor in the department of leukemia at MD Anderson Cancer Center, discusses how advances in the understanding of prognostic biomarkers may help guide the treatment of AML.

In this video, Ghayas C. Issa, MD, assistant professor in the department of leukemia at MD Anderson Cancer Center, discusses strategies for preventing relapse in patients with AML.

In this video, Ghayas C. Issa, MD, assistant professor in the department of leukemia at MD Anderson Cancer Center, discusses the biggest challenges in AML care today.

In this video, Ghayas C. Issa, MD, assistant professor in the department of leukemia at MD Anderson Cancer Center, discusses emerging and experimental therapies being researched for AML.

In this video, Ghayas C. Issa, MD, assistant professor in the department of leukemia at MD Anderson Cancer Center, discusses the latest advancements in treatment options for acute myeloid leukemia.

Lorlatinib appeared safe and showed potential efficacy among a cohort of patients with relapsed or refractory, ALK-driven, high-risk neuroblastoma, results of a phase 1 trial showed.

The FDA approved crizotinib for treatment of adults and children aged 1 year or older with anaplastic lymphoma kinase-positive unresectable, recurrent or refractory inflammatory myofibroblastic tumors.

CHICAGO — Retrospective data showed how common central nervous system metastases are among patients with non-small cell lung cancer and ALK or ROS1 alterations who have been treated with tyrosine kinase inhibitors.